Protocol deviations can be extremely costly to clinical trials, both financially and with patient safety. 💲 ⚕️ eClinical's Vera Pomerantseva recently spoke to Clinical Trials Arena's Abigail Beaney to share why the FDA could go further in its draft guidance, including examples to assist sponsors in implementation. Read the full interview: https://lnkd.in/e7yC-7CB
